---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-013785"
form_type: "8-K"
ticker: "TELO"
cik: "0001971532"
company_name: "Telomir Pharmaceuticals, Inc."
filed_at: "2026-03-31T23:59:59+00:00"
generated_at: "2026-05-15T08:15:33.368820+00:00"
event_type: "regulatory"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Telomir Pharmaceuticals submits IND to FDA for Telomir-1 in metastatic triple-negative breast cancer

## Summary
- IND submitted March 31, 2026 for oral Telomir-Zn (Telomir-1) in advanced/metastatic TNBC.
- Data from IND-enabling pharmacology, toxicology, and manufacturing studies included in submission.
- Planned Phase 1/2 trial: 3+3 dose-escalation, then Simon two-stage with ORR as primary endpoint.
- Preclinical GLP safety studies showed no treatment-related adverse or dose-limiting toxicities.
- Telomir-1 reduces redox-active iron and increases zinc, inhibiting iron-dependent histone demethylases.

## SEC filing metadata
- accession: 0001493152-26-013785
- form_type: 8-K
- ticker: TELO
- cik: 0001971532
- company_name: Telomir Pharmaceuticals, Inc.
- filed_at: 2026-03-31T23:59:59+00:00
- event_type: regulatory
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1971532/000149315226013785/0001493152-26-013785-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1971532/000149315226013785/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-013785
- JSON: https://secwatch.observer/filing/0001493152-26-013785.json
- Plain text: https://secwatch.observer/filing/0001493152-26-013785.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.